The following are excerpts from the newsletter
- Use of peritoneal dialysis
solution requires understanding of physiology behind process
- Four-pronged error analysis is "best practice"
- Safety Briefs:
- In cooperation with the Medication Errors Division
of FDA's Office of Postmarketing Drug Risk Assessment
(OPDRA), Monarch Pharmaceuticals, a division of King
Pharmaceuticals, has relabeled all strengths of KETALAR
(ketamine) injection to reduce medication errors.
Picture of new Ketalar packaging
- Rather than develop or revise an approved list of
medical abbreviations, JC allows you to deem a medical
abbreviation dictionary as the standard. Still, for
patient safety, you should have a list of dangerous
abbreviations that should never be used.
- FDA does not require companies to forward potential
errors with product labeling, packaging, and names when
reported by practitioners. To assure FDA, ISMP,
and USP awareness, report to the USP-ISMP Medication
Errors Reporting Program (800 23 ERROR) or FDA
MEDWATCH Program (1-800-FDA-1088).
- CDC has learned of numerous cases of inadequate treatment
of syphilis with BICILLIN C-R (a mixture of 1.2 million
units each of penicillin G benzathine and penicillin
G procaine). Instead, BICILLIN (which contains only
penicillin G benzathine) 2.4 million units should have